Inflammatory Bowel Diseases
s of ECCO
ECCO
Julien KIRCHGESNER | Professor (Associate) | MD, PhD | Hôpital Saint-Antoine (Hôpitaux Universitaires Est Parisien), Paris | Service d'Hépato-Gastro-Entérologie - Nutrition
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
PDF) P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study
European Crohn´s and Colitis Organisation - ECCO - The Council of National Representatives
Palle BAGER | Clinical Nurse Specialist / Senior researcher / Associate Professor at Aarhus University | RN, MPH, PhD | Aarhus University Hospital, Århus | AUH | Department of Hepatology and Gastroenterology
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
A continued story of success: Feeding science, digesting knowledge
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
European Crohn´s and Colitis Organisation - ECCO - The Council of National Representatives
European Crohn´s and Colitis Organisation - ECCO - The Council of National Representatives
European Crohn´s and Colitis Organisation - ECCO - Uncategorised
WINTER
NewsWINTER
PDF) The histopathological approach to inflammatory bowel disease: A practice guide
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
ECCO in Vienna was the Best Congress Ever!
PDF) Budesonide is superior to mesalazine in maintaining disease remission for patients with steroid-dependent Crohn's disease | Gerassimos Mantzaris - Academia.edu
Untitled
John TRIANTAFILLIDIS | Inflammatory Bowel Disease Unit, IASO General Hospital, Athens, Greece | Associate Professor, University of Medicine and Pharmacy, Iasi, Romania | IASO Hospital, Athens, Athens | IASO | IBD unit
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
